LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

ADMA Biologics Inc

Open

Branche Gesundheitswesen

10.62 1.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.58

Max

10.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

35M

18M

Verkäufe

8M

82M

EPS

0.08

Gewinnspanne

21.748

Angestellte

624

EBITDA

7.9M

24M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+0.57 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

266M

2.4B

Vorheriger Eröffnungskurs

8.8

Vorheriger Schlusskurs

10.62

Nachrichtenstimmung

By Acuity

25%

75%

47 / 370 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

ADMA Biologics Inc Chart

Ähnliche Nachrichten

18. Juni 2024, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia in Deal to Buy Software Startup Shoreline.io, Bloomberg Reports

18. Juni 2024, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Circle K, Global Partners Sell Dozens of U.S. Stores -- OPIS

18. Juni 2024, 21:36 UTC

Market Talk

Fitch Affirms Canadian Bank Ratings, Citing Pending BOC Rate Cuts -- Market Talk

18. Juni 2024, 20:59 UTC

Top News

Exxon Lawsuit Against Activist Shareholders Thrown Out -- WSJ

18. Juni 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover -- IBD

18. Juni 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juni 2024, 19:59 UTC

Market Talk

Canada Finance Officials Aware of 'Rebalancing' in Labor Market -- Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Gold Stays Elevated as Central Banks Continue To Buy -- Market Talk

18. Juni 2024, 19:17 UTC

Ergebnisse

Investors Shrugged Off Zyn's Latest Trouble. Nicotine Pouches Still Aren't in the Clear. -- Barrons.com

18. Juni 2024, 19:07 UTC

Market Talk

Oil Futures Advance as Traders Bet on Seasonal Demand -- Market Talk

18. Juni 2024, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

18. Juni 2024, 18:00 UTC

Top News

Amazon Fined by California for Failure to Disclose Worker Quotas -- WSJ

18. Juni 2024, 17:17 UTC

Market Talk

Brazil's Central Bank Expected To Pause Easing -- Market Talk

18. Juni 2024, 17:12 UTC

Market Talk

U.S. Home Prices Rise At Slowest Rate in Nearly 18 Months -- Market Talk

18. Juni 2024, 17:00 UTC

Ergebnisse

Kroger Earnings Due As Grocery Archrivals Walmart, Costco Snatch All-Time Highs -- IBD

18. Juni 2024, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 15:59 UTC

Akquisitionen, Fusionen, Übernahmen

Citi Stock Gains as Bank Showcases an Overlooked Business -- Barrons.com

18. Juni 2024, 15:37 UTC

Market Talk

Oil Gains on Expectations of Tighter Market Over Summer -- Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

German Economic Sentiment Has Plateaued, But Recovery Still on Track -- Market Talk

18. Juni 2024, 15:32 UTC

Market Talk

Some Steam Expected to Come Out of Gold Price as Rates Fall -- Market Talk

18. Juni 2024, 15:28 UTC

Market Talk

German Economic Sentiment Shrugs off Political Uncertainty -- Market Talk

18. Juni 2024, 15:00 UTC

Market Talk

Kering Will Continue to Face Challenges -- Market Talk

18. Juni 2024, 14:51 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Proxy ISS Supports BBVA's Bid for Sabadell -- Market Talk

Peer-Vergleich

Kursveränderung

ADMA Biologics Inc Prognose

Kursziel

By TipRanks

0.57% Vorteil

12-Monats-Prognose

Durchschnitt 10.5 USD  0.57%

Hoch 12 USD

Tief 10 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ADMA Biologics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

10.09 / 10.47Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

No Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

47 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.